These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35803533)

  • 21. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer.
    Paulmurugan R; Bhethanabotla R; Mishra K; Devulapally R; Foygel K; Sekar TV; Ananta JS; Massoud TF; Joy A
    Mol Cancer Ther; 2016 Feb; 15(2):221-31. PubMed ID: 26553061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
    Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
    Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
    Valcourt DM; Dang MN; Scully MA; Day ES
    ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined chemotherapy for triple negative breast cancer treatment by paclitaxel and niclosamide nanocrystals loaded thermosensitive hydrogel.
    Zhao D; Hu C; Fu Q; Lv H
    Eur J Pharm Sci; 2021 Dec; 167():105992. PubMed ID: 34517104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
    Lee SY; Cho HJ
    Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
    Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
    Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Copper-Free 'Click' Chemistry-Based Synthesis and Characterization of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia.
    Tatiparti K; Sau S; Gawde KA; Iyer AK
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
    J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
    He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
    Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Gibbens-Bandala B; Morales-Avila E; Ferro-Flores G; Santos-Cuevas C; Meléndez-Alafort L; Trujillo-Nolasco M; Ocampo-García B
    Mater Sci Eng C Mater Biol Appl; 2019 Dec; 105():110043. PubMed ID: 31546458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z; Jiang H; Zhu X; Liu X; Li J
    Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
    Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
    Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
    Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
    Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.